Moderna Swings to Q3 Profit of $162M, Raises Full-Year Revenue Growth Guidance
nashnova research
Moderna swung to a $162 million net profit in Q3, its first quarterly gain in nearly two years, as revenue jumped 29% to $1.31 billion — far above Wall Street's $885.1 million estimate; the company raised its full-year revenue growth guidance to 15%–25%, with its cancer-vaccine pipeline emerging as the linchpin of a broader re-rating.
What makes this quarter stand out?
Q3 net income hit $162 million ($0.38/share), reversing a $200 million loss a year ago. This is Moderna's first profitable quarter in nearly two years.
Revenue reached $1.31 billion, up 29% year-on-year. Wall Street expected $885.1 million. This means → actual revenue beat the most optimistic consensus by nearly 50%.
Management immediately raised full-year revenue growth guidance from "up to 10%" to 15%–25%. In plain terms = the company is signaling Q3 was not a one-off but a confirmation of the full-year trajectory.
Where is the money coming from — still Covid vaccines?
The U.S. contributed $780 million; international markets added $533 million. Growth in international Covid vaccine sales and deliveries under long-term government contracts drove the beat.
CEO Stéphane Bancel noted that the next-generation mRNA Covid vaccine — approved in May 2025 — is only now showing its "full-year impact." A standalone flu vaccine approved in August 2025 still has limited U.S. reach, with upside yet to materialize.
This reflects a key reality: nearly all of Moderna's revenue still comes from Covid vaccines. New-product contributions are just beginning, but geographic diversification is opening a second growth leg.
Why did a cancer vaccine send the stock up 177% in one day?
Moderna and Merck are co-developing a personalized melanoma vaccine — an mRNA shot custom-built from each patient's tumor genes. Positive late-stage trial data released in August sent Moderna's stock up 177% in a single session, triggering a massive short squeeze.
This means → the market treated the data as the key proof point for Moderna's transformation from "Covid vaccine company" to "mRNA platform company."
However, some trial data later leaked on social media before its formal presentation at a European medical conference, and the stock pulled back in October as views on commercialization potential diverged. Bancel called the reaction "surprising," noting that long-term investors and deep-dive analysts were positive, and that clinicians were "impressed" by the data.
Who is buying in and who is selling out?
Fidelity has tripled its Moderna stake since September 2025 and is now the company's largest shareholder. This means → a major long-only fund is betting on the cancer-vaccine pipeline's commercial payoff.
Baillie Gifford cut its holding from roughly 10% at end-2024 to about 4.5%, having publicly expressed "disappointment" with Moderna's direction.
In plain terms = two of the company's biggest shareholders have reached opposite conclusions — one sees a transformation opportunity, the other thinks delivery is too slow.
Has the political headwind faded?
Zach Lahn, the Republican gubernatorial candidate who proposed banning mRNA Covid vaccines in Iowa, lost the midterm election. U.S. Health Secretary Robert F. Kennedy Jr. campaigned for him — to no effect.
Moderna was once the most-shorted stock in the S&P 500. It is now the best-performing name in the index over the past year and was re-added to the Nasdaq-100 in October.
This reflects a weakening of political resistance to mRNA technology — but whether the cancer vaccine wins regulatory approval and reaches the market next year remains the critical test of whether the re-rating thesis can keep delivering.
市场有风险，内容仅供研究参考，不构成投资建议。